US2018100200A1PendingUtilityA1

Method of diagnosing neoplasms

60
Assignee: CLINICAL GENOMICS PTY LTDPriority: Oct 23, 2007Filed: Nov 10, 2017Published: Apr 12, 2018
Est. expiryOct 23, 2027(~1.3 yrs left)· nominal 20-yr term from priority
G01N 2800/06C12Q 2600/16C12Q 2600/112G01N 33/5753C12Q 2600/158C12Q 1/6886G01N 33/57446
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates generally to nucleic acid molecules, the RNA and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine neoplasm, such as an adenoma or an adenocarcinoma. The expression profiles of the present invention are useful in a range of applications including, but not limited to, those relating to the diagnosis and/or monitoring of colorectal neoplasms, such as colorectal adenocarcinomas. Accordingly, in a related aspect the present invention is directed to a method of screening a subject for the onset, predisposition to the onset and/or progression of a neoplasm by screening for modulation in the expression profile of one or more nucleic acid molecule markers.

Claims

exact text as granted — not AI-modified
1 . A method of screening for the onset or predisposition to the onset of a large intestine neoplasm or monitoring the progress of a neoplasm in an individual, said method comprising measuring the level of expression of one or more genes or transcripts selected from:
 (i) the gene, genes or transcripts detected by Affymetrix probeset IDs:
 205513_at; and/or 
   (ii) TCN1   in a biological sample from said individual wherein a higher level of expression of the genes or transcripts of group (i) and/or group (ii) relative to control levels is indicative of a neoplastic large intestine cell or a cell predisposed to the onset of a neoplastic state.   
     
     
         2 . The method according to  claim 1  wherein said control level is a non-neoplastic level. 
     
     
         3 . The method according to  claim 1  wherein said neoplastic cell is an adenoma or an adenocarcinoma. 
     
     
         4 . The method according to  claim 1  wherein said cell is a colorectal cell. 
     
     
         5 . The method according to  claim 1  wherein said biological sample is a faecal sample, enema wash, surgical resection, tissue biopsy or blood sample. 
     
     
         6 . The method according to  claim 1  wherein said level of expression is mRNA expression or protein expression. 
     
     
         7 . The method according to  claim 1  wherein said biological sample is a fecal sample, enema wash, surgical resection, tissue biopsy or blood sample. 
     
     
         8 . The method according to  claim 1  wherein said individual is a human.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.